Table 2.

Correlation Between ADAMTS9-AS2 Expression and Clinical Characteristics in LUAD

Characteristic	Low Expression of ADAMTS9-AS2	High Expression of ADAMTS9-AS2	p
n	267	268
T stage, n (%)			0.162
T1	79 (14.8%)	96 (18%)
T2	157 (29.5%)	132 (24.8%)
T3	24 (4.5%)	25 (4.7%)
T4	7 (1.3%)	12 (2.3%)
N stage, n (%)			0.044
N0	164 (31.6%)	184 (35.5%)
N1	54 (10.4%)	41 (7.9%)
N2	46 (8.9%)	28 (5.4%)
N3	1 (0.2%)	1 (0.2%)
M stage, n (%)			1.000
M0	182 (47.2%)	179 (46.4%)
M1	13 (3.4%)	12 (3.1%)
Primary therapy outcome, n (%)			0.388
PD	40 (9%)	31 (7%)
SD	20 (4.5%)	17 (3.8%)
PR	2 (0.4%)	4 (0.9%)
CR	156 (35%)	176 (39.5%)
Pathologic stage, n (%)			0.102
Stage I	135 (25.6%)	159 (30.2%)
Stage II	65 (12.3%)	58 (11%)
Stage III	51 (9.7%)	33 (6.3%)
Stage IV	13 (2.5%)	13 (2.5%)
Gender, n (%)			0.003
Female	125 (23.4%)	161 (30.1%)
Male	142 (26.5%)	107 (20%)
Race, n (%)			0.233
Asian	4 (0.9%)	3 (0.6%)
Black or African American	33 (7.1%)	22 (4.7%)
White	194 (41.5%)	212 (45.3%)
Age, n (%)			0.726
≤65	129 (25%)	126 (24.4%)
>65	127 (24.6%)	134 (26%)
Residual tumor, n (%)			0.315
R0	186 (50%)	169 (45.4%)
R1	4 (1.1%)	9 (2.4%)
R2	2 (0.5%)	2 (0.5%)
Anatomic neoplasm subdivision, n (%)			0.748
Left	104 (20%)	101 (19.4%)
Right	154 (29.6%)	161 (31%)
Anatomic neoplasm subdivision 2, n (%)			0.356
Central Lung	29 (15.3%)	33 (17.5%)
Peripheral Lung	70 (37%)	57 (30.2%)
Number_pack_years_smoked, n (%)			0.031
<40	89 (24.1%)	99 (26.8%)
≥40	107 (29%)	74 (20.1%)
Smoker, n (%)			< 0.001
No	22 (4.2%)	53 (10.2%)
Yes	239 (45.9%)	207 (39.7%)
Age, median (IQR)	65 (57, 72)	66 (60, 72)	0.211